Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 30, 2024

Myeloprotection With Trilaciclib in Chinese Patients With Extensive-Stage SCLC Receiving Chemotherapy

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)
Lung Cancer 2024 Feb 01;188(xx)107455, Y Cheng, L Wu, D Huang, Q Wang, Y Fan, X Zhang, H Fan, W Yao, B Liu, G Yu, Y Pan, F Xu, Z He, X Dong, R Ma, X Min, X Ge, H Chen, Q Liu, Y Hu, Y Liu, C Yang, Y Yang, X Li, L Zhou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading